www.innocyto.com.cn

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Anti-Human CTLA-4 (Tremelimumab Biosimilar)

Catalog Number:	506401, 506402, 506403
Size:	1 mg, 5 mg, 20 mg
Target Name:	CTLA4, CD152, CELIAC3, GSE, IDDM12
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	Tremelimumab
Application:	Flow cytometry, animal model study
Reactivity:	Human
Format:	Liquid
Product Description:	Tremelimumab Biosimilar, Human CTLA-4 monoclonal Antibody
Isotype:	Human IgG2
Clonality:	Recombinant
Immunogen:	Human CTLA-4
Species specificity:	Human
Purity:	>95% by reducing SDS-PAGE
Grade:	In vivo
Storage Conditions:	4ºC
Maximal Shelf Life:	12 months
Synonyms:	CD152
Antibody Type:	Recombinant
Reactivity:	Human

BACKGROUND INFORMATION

Tremelimumab is a fully human monoclonal antibody belonging to the immunoglobulin G2 (IgG2) subclass, designed to specifically bind to cytotoxic T-lymphocyte–associated protein 4 (CTLA-4, also known as CD152). Structurally, it is a glycoprotein with an approximate molecular weight of 147 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains joined by interchain disulfide bonds, forming the classic Y-shaped IgG configuration. Each heavy chain includes one variable (VH) and three constant (CH1-CH3) domains, while each light chain comprises one variable (VL) and one constant (CL) domain. Tremelimumab is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring correct folding, assembly, and human-like glycosylation.

The complementarity-determining regions (CDRs) within Tremelimumab’s variable domains define its high-affinity and specific recognition of an epitope on the extracellular portion of CTLA-4. CTLA-4 is an immune checkpoint receptor expressed on activated T

cells and regulatory T cells, functioning as an inhibitory regulator of T-cell signaling. Tremelimumab binds to CTLA-4 with nanomolar affinity through a network of hydrogen bonds and hydrophobic interactions, preventing CTLA-4 from engaging its natural ligands, CD80 (B7-1) and CD86 (B7-2), on antigen-presenting cells. By blocking this interaction, the antibody inhibits the suppressive signaling pathways normally mediated by CTLA-4, thereby facilitating the co-stimulatory interaction between CD28 and B7 molecules in experimental immunological systems. This results in enhanced T-cell activation and proliferation through the modulation of intracellular kinases and transcriptional regulators such as ZAP-70 and NFAT.

This product is supplied subject to the terms and conditions at www.innocyto.com.cn/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.